Illia Terpylo

7 fronts where Big Pharma explores AI via partnerships and internal programs.

The traditional drug discovery process is among the most complex, costly, and time-consuming endeavors in science. Developing a single medicine might take over a decade of …

Tech giants are becoming part of biopharma’s infrastructure, applying AI, data, and cloud to drug discovery as they seek footholds in new markets.

Large technology companies aren’t newcomers to biopharma and healthcare, but now there’s less theater around “disruption” …

Healx, a drug discovery company founded by Tim Guilliams, a Cambridge-trained tech entrepreneur, and David Brown, the co-inventor of Viagra, has entered into a strategic collaboration with Vuja De Sciences to integrate Vuja’s cancer expertise with their Healx’s platform. …

Researchers at Stanford University and the Arc Institute report they used a genome-scale generative model to design novel variants of bacteriophage phiX174; 16 of 302 AI-proposed genomes replicated in E. coli and lysed bacteria, indicating functional “AI-written” viruses suitable …

Causaly has announced Causaly Agentic Research, a new AI platform designed to support life sciences R&D with domain-specific “agentic” AI. The system aims to outperform literature review tools and general-purpose AI by combining internal and external biomedical data …

Google Research introduced a Gemini-based system that writes and iteratively improves “empirical software,” with a preprint and an interactive site showing full solution trees. The system treats well-defined scientific problems as scorable tasks and targets a single objective metric, reporting …

From public labs to private stations, the near-term outlook for orbital bioprocessing and its first commercial pipelines

The renewed surge in space ambition extends beyond rockets and habitats by driving the integration of biotechnology into orbit. As humanity prepares …

LatchBio has released a human spatial transcriptomics atlas of 25 million cells. Covering 45 tissue types, 63 diseases, and data from 11 major platforms (10X Genomics, Bruker CosMx, STOmics Stereo-seq, Vizgen MERSCOPE, Takara Bio Seeker, AtlasXOmics DBiT-seq, Spatial Genomics …

Pathology has progressed from glass slides to AI-driven digital diagnostics, promising to transform disease detection while facing adoption and market challenges

Bo Wang, Head of Biomedical AI at Xaira Therapeutics, puts it simply: “Pathology is the cornerstone …

From early 2000s and a 2012 milestone to a decade-long quiet—virtual cell modeling is resurging with transformers, perturbation atlases, and lab-in-the-loop systems

While the term “virtual cell” initially goes back to the early 2000s from the Trends in Biotechnology …